Answers are grounded in this paper and cite their sources.
Modeling demonstrates improved survival and lower costs with rapid diagnostic testing for bloodstream infections, suggesting significant benefits.
The model demonstrated improved patient survival and reduced average total costs with mRDT. The Cobas Eplex BCID panels, which have the largest pathogen coverage, reduced both mortality and overall costs compared with other mRDTs.
No takes yet. Share an insight, caveat, or question.
Karichu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: